AFP and hepatocellular carcinoma: In a phase 2 prospective clinical trial, HelioLiver Test, which combined cfDNA methylation patterns with clinical characteristics and protein tumor markers, showed sensitivity of 85% for any or early stage (76%) of HCC diagnosis performing better than AFP and GALAD score and having similarly high specificity (>90%) [35].